Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +47.25%
#2 Pons Pons +44.07%
#3 Mubarak Mubarak +38.95%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +30.27%
#5 Starpower Starpower +28.10%
#6 SkyAI SkyAI +24.07%
#7 TENDIES TENDIES +23.33%
#8 Decred Decred +20.80%
#9 Degen (Base) Degen (Base) +20.08%
#10 StonkBroker StonkBroker +18.13%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
SynCore Biotechnology Co.,Ltd SynCore Biotechnology Co.,Ltd

SynCore Biotechnology Co.,Ltd

4192
Kedudukan dalam Saham #29320
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Harga Saham
$0.62008105
Disegerakkan terakhir: 2026-08-18
Modal Pasaran
$21.81M
Perubahan (1 hari)
0.26%
Perubahan (1 tahun)
-31.95%
Negara
TW
Perdagangan SynCore Biotechnology Co.,Ltd (4192)

Kategori

Healthcare
Hasil untuk SynCore Biotechnology Co.,Ltd (4192)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada SynCore Biotechnology Co.,Ltd, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi SynCore Biotechnology Co.,Ltd dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH